Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
about
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsMiltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical StudyRational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.Cytotoxic and antiangiogenic paclitaxel solubilized and permeation-enhanced by natural product nanoparticles.Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.A critical review of lipid-based nanoparticles for taxane delivery.Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distributionHydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterizationIntestinal permeability and its relevance for absorption and elimination.Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs.Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model.Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers.Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake.Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation.Nanocarriers for oral drug delivery.Recent advancements in mechanical reduction methods: particulate systems.The application of nanosponges to cancer drug delivery.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations.Advances in oral delivery of anti-cancer prodrugs.In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.Liposome-targeted delivery for highly potent drugs.Lipid nanocapsule-based gels for enhancement of transdermal delivery of ketorolac tromethamine.Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies.In vivo Evaluation of Self Emulsifying Drug Delivery System for Oral Delivery of Nevirapine.The use of endophytes to obtain bioactive compounds and their application in biotransformation process.Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.Fungal biotransformation of tanshinone results in [4+2] cycloaddition with sorbicillinol: evidence for enzyme catalysis and increased antibacterial activity.Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.Liposome-encapsulated midazolam for oral administration.A hederagenin saponin isolated from Clematis ganpiniana induces apoptosis in breast cancer cells via the mitochondrial pathway.Nanoformulated water-soluble paclitaxel to enhance drug efficacy and reduce hemolysis side effect.KNApSAcK-3D: a three-dimensional structure database of plant metabolites.Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study.
P2860
Q26996159-9DA0A34A-93B6-4CE9-8299-6D065161078CQ28551006-D189CF10-E797-4ECE-8868-CF89E9A825E2Q30436623-B587EF67-6CB6-4EB1-8CAB-5C439FF3402DQ34747035-0B4AC420-6192-43E2-A3FA-E3504D3781E0Q36240183-071A14D1-39D5-4CA4-978B-0A33A1A25AC3Q36360764-53A6FB61-0E28-468A-8091-8EA23923BA67Q36659315-C46B42E0-FBE1-4BC2-BF49-CFE1F7B13912Q36868666-6DBFF257-A66C-4B57-A6C6-E7D6C721DDD0Q36985043-658DE344-912C-4CF0-9ABF-D80D5829274AQ37141404-895A2CC6-2DD9-4E1A-8260-ED7C300F80BFQ37194117-4741AFFB-4062-41DD-BD74-C24F172EAD13Q37278642-6ABE60F7-9F6F-47D9-8803-6562749FF953Q37282649-56AE6A72-AC5F-4A93-809D-F6F81C06FC85Q37490613-BD35384E-3ABD-48FC-8C87-3B50CEDCE198Q37714256-FC1BA692-9BD0-497D-A08F-169C40E18031Q38101960-17A02583-B7CB-49EB-AC2A-11EED5CD95C2Q38132471-04C8C903-FA1A-4805-B1E2-B9C103A3A453Q38210423-E4087EA9-D05F-4D2F-864E-9FDDBE17AF3CQ38340831-3668A782-67AD-4363-B766-28F8CA5BB9EAQ38800427-C0B822E0-589F-451F-B1F2-9DDE8BF7AE25Q38862820-A9FC50BD-D273-4421-BA6C-4E655399BB90Q38905471-778BB0C1-68BB-4F04-A71C-3442B4D22520Q39171223-26CBBB85-4D02-4F9D-822B-D1FE31822E9BQ39518672-D45E92B7-406F-44DB-A703-B992293A1E30Q39598850-22171963-0454-495F-A9D3-77EEB098957EQ39735209-453D4A5E-E72B-4CFF-B30C-061C584C0C04Q39765023-FDCE19B2-D49C-496E-9A9A-E8E6A92E0B12Q39856908-738000BB-8ADD-44DB-A4C0-A6ADFFB4CD8CQ41988569-36B4430C-4B55-4944-A8D9-43671EB2FCFFQ42006799-FFD1D8B2-8BF0-4CDB-A3BE-7B28ACB03F69Q42205568-00E70889-28A8-4771-8B83-2457AD8A4087Q42620744-BE89BB11-777D-429A-B381-9D21D9BDAE10Q42910331-9FAE93F9-6B51-4507-A5A8-30102649B669Q46172298-DB69D1AA-E6E8-4552-822F-5F8DA50B7876Q47121521-83C80363-87AE-4AEB-9BE2-3501CF751C78Q48337514-9F61E32F-1F54-4EDA-8934-122B8B4FE8D1Q49519221-4DDDC080-0C7B-43E2-8D8A-6FC3B2B8C09FQ50875323-B54A0C63-23BB-4002-A698-5943A8517658Q51280021-99C88A44-4858-4B04-91BF-2E8D73F408B7Q51307074-66FA7A16-606B-44FC-8202-F0D21D1CCFAF
P2860
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@ast
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@en
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@nl
type
label
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@ast
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@en
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@nl
prefLabel
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@ast
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@en
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@nl
P2093
P1476
Enhanced oral paclitaxel bioav ...... xel-loaded lipid nanocapsules.
@en
P2093
Jean-Michel Oger
Jean-Pierre Benoît
Sandra Peltier
P2860
P304
P356
10.1007/S11095-006-0022-2
P577
2006-05-25T00:00:00Z